| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/CPT.693 |
| P698 | PubMed publication ID | 28378901 |
| P2093 | author name string | T van Gelder | |
| B C Jacobs | |||
| P A van Doorn | |||
| Bcp Koch | |||
| Crb Ramakers | |||
| Wjr Fokkink | |||
| P2860 | cites work | Pharmacokinetics of intravenous immunoglobulin: a systematic review. | Q33371277 |
| PKSolver: An add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel | Q33533523 | ||
| IgG subclasses and allotypes: from structure to effector functions | Q34368678 | ||
| European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Pe | Q34619228 | ||
| An update on the management of chronic inflammatory demyelinating polyneuropathy | Q34645179 | ||
| FcRn: the neonatal Fc receptor comes of age. | Q36912134 | ||
| The role of IVIg in autoimmune neuropathies: the latest evidence | Q37237413 | ||
| Pharmacokinetics of immunoglobulin administered via intravenous or subcutaneous routes | Q37304914 | ||
| Structure and function of immunoglobulins | Q37696721 | ||
| Optimizing IgG therapy in chronic autoimmune neuropathies: a hypothesis driven approach | Q38270717 | ||
| Potential Sources of Inter-Subject Variability in Monoclonal Antibody Pharmacokinetics | Q38714339 | ||
| Intravenous and subcutaneous immunoglobulin G replacement therapy | Q39033039 | ||
| Immunoglobulin G level variations in treated chronic inflammatory demyelinating polyneuropathy: clues for future treatment regimens? | Q39424607 | ||
| Competition for FcRn-mediated transport gives rise to short half-life of human IgG3 and offers therapeutic potential | Q39424805 | ||
| Rasch-built Overall Disability Scale (R-ODS) for immune-mediated peripheral neuropathies. | Q39790328 | ||
| Confirming the efficacy of intravenous immunoglobulin in CIDP through minimum clinically important differences: shifting from statistical significance to clinical relevance | Q39854887 | ||
| Improving fatigue assessment in immune-mediated neuropathies: the modified Rasch-built fatigue severity scale | Q39917840 | ||
| Variability in intravenous immunoglobulin G regimens for autoimmune neuromuscular disorders | Q45640650 | ||
| Pharmacokinetics of a new 10% intravenous immunoglobulin in patients receiving replacement therapy for primary immunodeficiency. | Q45985490 | ||
| Pharmacokinetics of intravenous immunoglobulin in multifocal motor neuropathy. | Q46020925 | ||
| Long-term outcome in chronic inflammatory demyelinating polyneuropathy patients treated with intravenous immunoglobulin: a retrospective study. | Q46887163 | ||
| Monitoring intravenous immunoglobulin dosing regimens in chronic inflammatory demyelinating polyneuropathy: search for a biomarker | Q46939825 | ||
| Association of Albumin Levels With Outcome in Intravenous Immunoglobulin-Treated Guillain-Barré Syndrome | Q48010804 | ||
| Optimization of intravenous immunoglobulin in chronic inflammatory demyelinating polyneuropathy evaluated by grip strength measurement. | Q50882404 | ||
| Analytical performances of SPAPLUS® turbidimeter for the quantification of albumin and IgG in serum and cerebrospinal fluid. | Q51390694 | ||
| Long-term immunoglobulin therapy for chronic inflammatory demyelinating polyradiculoneuropathy. | Q53646810 | ||
| Clinical and electrophysiologic correlates of IVIg responsiveness in CIDP. | Q53859826 | ||
| European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Pe | Q55052893 | ||
| Confidence interval for a coefficient of quartile variation | Q56766661 | ||
| Alterations in the half-life and clearance of IgG during therapy with intravenous gamma-globulin in 16 patients with severe primary humoral immunodeficiency | Q68966153 | ||
| Individual patient variations in the kinetics of intravenous immune globulin administration | Q70240009 | ||
| Pharmacokinetic characteristics and tolerability of a novel intravenous immunoglobulin preparation | Q71149802 | ||
| Multifocal motor neuropathy: diagnostic criteria that predict the response to immunoglobulin treatment | Q73298577 | ||
| Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial | Q80454073 | ||
| Pharmacokinetics of intravenous immunoglobulin and outcome in Guillain-Barré syndrome | Q84950858 | ||
| Serum IgG levels in IV immunoglobulin treated chronic inflammatory demyelinating polyneuropathy | Q86503267 | ||
| Subcutaneous vs. intravenous immunoglobulin in CIDP: pharmacokinetic and clinical response | Q89348404 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pharmacokinetics | Q323936 |
| pharmacodynamics | Q725307 | ||
| P304 | page(s) | 709-716 | |
| P577 | publication date | 2017-04-05 | |
| P1433 | published in | Clinical Pharmacology & Therapeutics | Q1101529 |
| P1476 | title | Pharmacokinetics and Pharmacodynamics of Intravenous Immunoglobulin G Maintenance Therapy in Chronic Immune-mediated Neuropathies. | |
| P478 | volume | 102 |
| Q55465940 | Adverse Effects of Immunoglobulin Therapy. |
| Q60933975 | IVIg-induced plasmablasts in patients with Guillain-Barré syndrome |
| Q64059420 | Lifelong immunoglobulin replacement is not always necessary: A case description of a patient with recurrent infections and hypogammaglobulinemia |
| Q91927169 | Progress in diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy |
Search more.